Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Abbott

Status: Completed

Conditions: Human Immunodeficiency Virus-Infection

Treatments: Drug: Lopinavir/Ritonavir (Kaletra)

Study type: Observational

Funder types: Industry

Identifiers

NCT01153269

KAL 1 HO

Details and patient eligibility

About

The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients infected by HIV-1 and HBV or HCV
• Age ≥18 years
• Patients who were initiated on a LPV/r containing antiretroviral (ARV) regimen

Exclusion criteria

• Contraindications as described in SmPC (summary of product characteristics) at the time of prescription

Trial design

33 participants in 1 patient group

HIV-infected patients with hepatitis co-infection

Description:

HIV-infected patients with co-infections of Hepatitis B or Hepatitis C

Treatment:

Drug: Lopinavir/Ritonavir (Kaletra)